SCHEMBL3534223

SCHEMBL3534223

Nc1ccc(C=O)cc1CS(=O)(=O)c1cccc2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
CA2 P00918 2/20 0.42
CA1 P00915 1/20 0.42
CA9 Q16790 1/20 0.42
HTR6 P50406 1/20 0.40
F2 P00734 3/20 0.37
PRSS1 P07477 3/20 0.37
PRSS2 P07478 3/20 0.37
PRSS3 P35030 3/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
HDAC1 Q13547 2/20 0.36
ALDH1A1 P00352 3/20 0.35
SCN1A P35498 2/20 0.35
SCN2A Q99250 2/20 0.35
SCN3A Q9NY46 2/20 0.35
CYP3A4 P08684 2/20 0.35
HSD17B10 Q99714 2/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3531827 0.81 ALDH1A1 (0.42) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL3532950 0.76 HTR6 (0.40) CA2CA1CA9HTR6
SCHEMBL3528998 0.75 ALDH1A1 (0.46) NPC1RAB9ACA2CA1CA9
SCHEMBL3533663 0.75 CA2 (0.38) CA2CA1CA9HTR6F2
SCHEMBL4278946 0.74 HTR6 (0.56) HTR6KDM4EMAPT
SCHEMBL14610862 0.73 F2 (0.42) NPC1RAB9ACA2CA1CA9
SCHEMBL3531052 0.72 PTPN1 (0.40) HTR6F2PRSS1PRSS2PRSS3
SCHEMBL8233317 0.71 HTR6 (0.38) CA1CA9HTR6F2KMT2A
SCHEMBL3531438 0.71 CA12 (0.47) CA1CA9HTR6F2ALDH1A1
SCHEMBL3533435 0.70 HTR6 (0.38) CA2CA1CA9HTR6F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723329-B2 Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands WYETH LLC (US) 2010-05-25 US disclosed
EP-1931640-A2 SUBSTITUTED-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS Wyeth a Corporation of the State of Delaware (US) 2008-06-18 EP disclosed
WO-2007021711-A2 SUBSTITUTED-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2007-02-22 WO disclosed
US-20070037802-A1 such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders WYETH (US) 2007-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037802-A1 such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders HTR6, TPH1, HTR1A NPC1 478/4885RAB9A 3414/4885CA2 4471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.